What is Biorce?
Biorce is at the forefront of revolutionizing clinical trials through its proprietary AI-native platform, Aika. This advanced solution streamlines critical processes such as protocol creation, feasibility analysis, and regulatory planning. By empowering clinical teams with enhanced efficiency, Biorce aims to drastically reduce protocol amendments and lower operational expenditures. This ultimately accelerates patient access to novel treatments. The company serves a global clientele, spanning clinical trial teams across the US, EU, and APAC, underscoring its ambition to redefine precision and efficiency in the drug development lifecycle. The platform's development is backed by a team of experts in clinical research and artificial intelligence, positioning Biorce as a transformative force in the healthcare technology sector.
How much funding has Biorce raised?
Biorce has raised a total of $94.9M across 3 funding rounds:
Other Financing Round
$37M
Other Financing Round
$5.9M
Series A
$52M
Other Financing Round (2024): $37M with participation from Plug and Play Tech Center, YZR Capital, and MSM fund (Mustard Seed Maze
Other Financing Round (2025): $5.9M led by Norrsken Vc
Series A (2026): $52M supported by YZR Capital, Norrsken Vc, DST Global, and MSM fund (Mustard Seed Maze
Key Investors in Biorce
MSM fund (Mustard Seed Maze
MSM Impact VC Fund is an investment firm focused on supporting fast-growing European ventures that address social and environmental challenges. The company aims to create a positive impact while ensuring financial returns for its clients.
YZR Capital
YZR Capital is an independent investment platform focused on supporting ambitious HealthTech founders in Europe who are addressing complex healthcare challenges. The company provides capital, deep sector expertise, and hands-on support to help build global champions in the healthcare sector.
Norrsken Vc
Norrsken VC is Europe's leading early-stage impact investor, focusing on companies that address significant global challenges while achieving substantial business growth. The firm invests across all 17 Sustainable Development Goals (SDGs) and emphasizes the importance of measurable impact tied to investment returns.
What's next for Biorce?
With the recent infusion of $52M in a major strategic investment, Biorce is poised for significant expansion and further development of its Aika platform. This capital injection, part of its $94.9M in total funding, suggests a transition into a scaling phase, likely focusing on market penetration, technological enhancement, and broadening its global reach. The strategic nature of this investment indicates a focus on long-term growth and market leadership in the clinical trial acceleration space. Future initiatives will likely involve deepening AI capabilities, expanding service offerings, and forging strategic partnerships to further optimize the drug development pipeline and bring life-saving therapies to patients faster.
See full Biorce company page
